)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Insight Molecular Diagnostics
Insight Molecular Diagnostics (IMDX) investor relations material
Insight Molecular Diagnostics KOL event summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.KOL event summary17 Aug, 2026
Introduction and agenda
The session focused on advances in donor-derived cell-free DNA (dd-cfDNA) testing for heart transplant surveillance, featuring a fireside chat and Q&A with a leading transplant cardiologist.
Discussion included the evolution of transplant monitoring, current protocols, and the potential impact of new in-house dd-cfDNA assays.
KOL background and credentials
Dr. Max Liebo, a transplant cardiologist at Loyola University, has over a decade of experience using molecular surveillance in heart transplant patients.
He has participated in major registries and has experience with multiple dd-cfDNA products.
Market insights and analysis
Heart transplant rejection surveillance has shifted from frequent invasive biopsies to non-invasive molecular assays over the past decade.
Recent guidelines and literature increasingly support dd-cfDNA as a primary tool for rejection monitoring.
Adoption barriers include logistical challenges, inertia in protocol updates, and the need for more real-world data.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Insight Molecular Diagnostics
- Innovative transplant monitoring kits drive decentralized diagnostics in a $3B global market.IMDX
Investor presentation - FDA review advances, Medicare expands coverage, and Q2 loss narrows on cost discipline.IMDXQ2 2026
- Minimal Q1 revenue as focus shifts to FDA approval and commercialization of transplant assay.IMDXQ1 2026
- Decentralized diagnostic kits and strong partnerships drive growth in transplant monitoring.IMDXInvestor presentation
- Virtual meeting to elect directors, ratify auditor, approve pay, and expand equity plan.IMDXProxy filing
- Proxy covers director elections, auditor ratification, compensation, and equity plan expansion.IMDXProxy filing
- GraftAssure's decentralized PCR test drives transplant diagnostics innovation and market expansion.IMDX25th Annual Needham Virtual Healthcare Conference
- Patent-protected transplant test nears FDA submission, targeting rapid, high-margin adoption.IMDXH.C. Wainwright 27th Annual Global Investment Conference
- GraftAssure's launch, Bio-Rad deal, and capital raise set the stage for future high-margin growth.IMDXQ2 2024
Next Insight Molecular Diagnostics earnings date
Q3 202616 Nov, 2026
Insight Molecular Diagnostics
Next Insight Molecular Diagnostics earnings date
Q3 202616 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
OncoCyte Corporation develops and markets molecular diagnostics for use in oncology and transplantation. The company focuses on liquid biopsy technologies and gene expression testing to support clinical decision-making in patient care. Its services are aimed at healthcare providers and research institutions. The company is headquartered in Irvine, California, and its shares are listed on the NASDAQ.